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Abstract
Too controversial to discuss only a short time ago, achieving a cure for HIV infection has become 
a priority in HIV research. However, substantial challenges must be overcome. Among key 
hurdles to be surmounted is the definition of a reliable, validated model in which to test latency 
reversal agents (LRAs), as current primary cell models differ in their response to such agents. 
Animal models such as the HIV-infected humanized BLT mouse and SIV-infected macaque will 
be essential to study LRAs, and to quantify their effects in anatomic reservoirs. Of several 
potential anatomic reservoirs, the central nervous system presents a significant obstacle, as it is 
known to harbor persistent HIV infection, and is difficult to access for study and therapeutic 
intervention.
Many obstacles stand in the way of efforts to target latent HIV infection with the goal of 
eradication, chief among them the dilemma of identifying all relevant cellular and anatomic 
reservoirs of latent, persistent infection, and determining whether virus in those reservoirs is 
able to be reactivated. Thus far, the cellular reservoir that exists within the resting central 
memory CD4+T cells is the best characterized, however many other potential sanctuaries 
have been described. Most recently, the newly-described stem-like T memory cells (Buzon 
et al, 2014), and γδ T cells (Soriano-Sarabia et al, 2013) have been reported to harbor latent 
HIV infection. Virus has long been thought to persist in macrophages, and specific strategies 
may be required to address persistence within these cells. In addition and of substantial 
importance, HIV may hide in anatomic compartments such as the central nervous system 
(CNS).
Timothy Ray Brown, known as the “Berlin Patient,” is the first reported case of HIV cure 
(Hutter et al, 2009). HIV-infected and diagnosed with acute myeloid leukemia, Mr. Brown 
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underwent two stem cell transplantations from an unrelated donor who was homozygous 
CCR5 32 mutation, and so donor cells were absolutely resistant to CCR5-using HIV strains. 
More than six years after the transplant, plasma HIV viral load and PBMCs DNA remain 
undetectable in the absence of antiretroviral therapy (Yukl et al, 2013). This inspiring case 
encouraged similar studies, and thus two HIV-infected individuals also suffering from 
lymphoma interrupted therapy after bone marrow transplant. These “Boston Patients,” 
however, remained without viremia for only 12 and 31 weeks. Several reasons could have 
accounted for this disappointing outcome, including a less intense preconditioning protocol, 
and the lack of a transplant with the CCR5 32 phenotype. However, before interrupting 
therapy, patients were tested and found to be negative for HIV-DNA in PBMCs, as well as 
without plasma viremia. Perhaps viral rebound was due to release of virus from anatomic 
reservoirs, such as the CNS. CNS reservoirs add a level of complexity to attempts to cure 
HIV infection, due to the uncertain access of therapeutic interventions, and the difficulty of 
sampling and studying the events in this privileged site.
Genetic compartmentalization in the CNS in the absence of antiretroviral treatment failure 
has been observed, suggesting autonomous viral evolution within the CNS (Harrington et al, 
2009). However treatment intensification with raltegravir did not alter CSF viral load 
measured by single-copy assay (Dahl et al, 2011), suggesting that ongoing viral evolution 
within the CNS may not occur during ART.
The CNS is distinguished by the selective permeability of the blood brain barrier (BBB). 
Comprised of a basement membrane, brain endothelial cells, pericytes and astrocytes, in 
addition to efflux pumps and enzymes, the BBB reduces the entry of many small molecule 
drugs, creating a potential pharmacologic sanctuary. The capacity to penetrate the brain 
differs among the different antiretroviral drugs, and an index has been developed to reflect 
this: CNS penetration effectiveness (Letendre et al, 2010). CPE classifies drugs in four 
groups according to their penetration into the CNS, ranging from 1 (poor penetration) to 4 
(high penetration). This score has been correlated with cerebrospinal fluid (CSF) viremia 
(Cusini et al, 2013) and neurocognitive dysfunction (Ciccarelli et al, 2013). However, 
obvious sampling limitations exist to accurately measure the magnitude of infection in the 
CNS, and for instance virus levels in the brain parenchyma can only be quantitated upon 
autopsy, and might differ from CSF measures. It is believed that improved drug delivery to 
the CNS will reduce the underlying persisting infection in the CNS and thus reduce the 
establishments of reservoirs. A proposed strategy to achieve this enhanced delivery of ART 
includes the use of nanotechnology. Nanoparticles (NPs) are solid colloidal particles in the 
nanometer range which can be used as delivery systems by absorption, entrapment or 
covalent attachment of therapeutic drugs. Several different types of nanoparticles have been 
developed differing in their nature, such as liposomes, dendrimers, micelles and inorganic 
crystals (Sanvicens and Marco, 2008). In addition, some antiretroviral drugs can be 
nanoformulated and carried into monocyte-derived macrophages (Dou et al, 2009). These 
systems have proven to increase CNS drug penetration, in addition to offering potential for 
further benefits including the simultaneous deliver of different molecules or the increase of 
the drug bioavailability. Gold nanoparticles (AuNPs) comprise an interesting nanoparticle 
approach to be used for HIV therapy. Its small size, ~2nm diameter, inert nature and 
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multivalency make them attractive as carrier for drugs. AuNPs can be conjugated with an 
entry inhibitor and exert antiviral activity (Bowman et al, 2008). In addition, entry of AuNPs 
has been demonstrated in lymphocytes, macrophages and microendothelial cells, without 
observable short-term toxicity. Further, such particles can be fabricated to display 
conjugates of raltegravir, an HIV integrase inhibitor, and inhibit viral replication. Finally 
AuNPs cross the BBB and can be found in the brain parenchyma in mice (Garrido et al, 
2013)
Currently, several efforts to eliminate the HIV reservoir begin with the concept of reversing 
latency within resting CD4+ T cells with small molecules that target host mechanisms 
crucial for the maintenance of latency. Not unexpectedly, recent studies suggest that 
disruption of latency will not necessarily result in the uniform and prompt death of infected 
cells from viral cytopathic effect (figure 1). Thus a consensus is emerging that enhancement 
of the antiviral immune response will be required as a component of eradication protocols 
(Shan et al, 2012).
Vorinostat, a histone deacetylase inhibitor (HDACi) used for the treatment of cutaneous T 
cell lymphoma, can disrupt HIV latency in vivo, as shown in a clinical trial in HIV-infected 
patients on antiretroviral therapy (Archin et al, 2012). However, in vitro studies recently 
suggest that a single pulse of HDACi would reactivate a tiny minority of infected cells (Cillo 
et al, 2014) , and with this in mind many groups are seeking combination approaches to 
more effectively purge latent reservoirs (Bullen et al, 2014) . A clinical trial evaluated 
recently the outcome of the administration of multiples doses of vorinostat , but the dosing 
schedule used was unable to demonstrate repeated induction of HIV RNA expression of the 
magnitude seen on the initial dose (Archin et al, 2014a).
Measuring the latent reservoir and documenting the effect of latency reversal agents has 
been unexpectedly difficult. DNA quantification by quantitative PCR (qPCR) was first used 
to measure the amount of infected cells, but this methodology will not give information 
about the proportion of replicative competent virus contained in those genomes, ultimately 
responsible for new cycles of infection (Eriksson et al, 2013). Therefore, the quantitative 
viral outgrowth assay (QVOA) is considered the gold standard to assess the magnitude of 
the reservoir, since it is the way of detecting replication competent virus (Archin et al, 2008; 
Siliciano and Siliciano, 2005). Unfortunately, viral outgrowth measured by QVOA appears 
to be a minimal estimate in at least 50% of patients (and a large underestimate in some), as a 
significant proportion of proviral DNA encodes proviruses that remain non-induced after a 
single maximal ex vivo stimulus, but are potentially productive of replication competent 
virus (Ho et al, 2013). However, besides the unquestioned relevance of replication 
competent proviruses, we should also consider the possibility that defective proviruses 
unable to produce viral particles may still express viral proteins, whose production may 
contribute to immune activation or trigger CD4+T cell apoptosis (Finzi et al, 2006). Thus, 
the clearance of infected cells may have to extend to those that produce antigen as well as 
functional virions.
It is essential to define experimental systems that allow the study of HIV eradication 
approaches. Ex vivo study of patient cells provide an important, if imperfect, model in 
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which latency disruption can be tested, but as less than 1 in a million CD4+T cells are 
latently infected, it is demanding to measure the effect of drugs or compare different 
interventions in this setting. Nevertheless, when carefully performed, this system is robust, 
reproducible, and sensitive (Archin et al, 2014b).
Alternatively, many studies of viral persistence can be conducted in cell or animal models 
(table 1). There are several primary cell models to study latency reversal developed so far, 
differing in the viral strain, cell subset and mechanism used to establish latency. A recent 
study compared the response of several primary T cell models, J-Lat cell models and the 
patient cell viral outgrowth assay to a panel of various latency reversal agents. None of the 
in vitro cell models alone was in complete agreement with the ex vivo response of latently 
infected T cells from patients (Spina et al, 2013), and hence observations using even 
primary cell models is imperfect, each model perhaps giving a representation of a subset of 
the in vivo latently infected reservoir. The ultimate approach to investigate eradication 
strategies is perhaps the use of animal models. In the last several years, the development of 
humanized mouse models has added a powerful tool to study therapeutic interventions, in 
addition to those previously performed in non-human primates. An impressive study by 
Denton at al. (Denton et al, 2014) recently used a combination of ART and an immunotoxin 
to measure depletion of persistent infection. However, thus far true anatomic reservoirs such 
as the CNS have been studied most extensively in primate models (Clements et al, 2011).
Some clinical trials are taking place to evaluate therapeutic strategies towards HIV cure. 
Generally, outcomes of these trials are evaluated using peripheral blood samples, since 
blood is the most accessible compartment and represent the systemic effects. However, it is 
important to additionally evaluate treatment outcomes in other HIV reservoirs such as the 
CNS. Three main different types of assessment can be performed to evaluate HIV infection 
in the CNS: surrogate biomarkers in CSF, neurocognitive testing and imaging techniques. 
Biomarkers are usually analyzed in the CSF, and include HIV-RNA viral load, neopterin 
levels, neurofilament light chain protein (NFL), tau protein and precursors and products of 
amyloid protein (Spudich and Gonzalez-Scarano, 2012). However, CSF sampling is an 
invasive technique which cannot be performed frequently. Therefore, non-invasive tests are 
desirable for CNS evaluation. A wide range of standardized neuropsychological tests can be 
used to identify subclinical deficits. These exams may include psychomotor speed tests, 
hand-eye coordination, ability to register and recall memories, attention and concentration, 
problem-solving capability and language abilities. Sacktor and colleagues (Sacktor et al, 
2005) developed the International HIV Dementia Scale (IHDS), consisting on three different 
tests - motor speed, psychomotor speed and memory-recall - which provides a score 
according to performance. There are also a number of neuroimaging techniques used to 
assess HIV-associated neurocognitive disorders, such as magnetic resonance spectroscopy 
(MRS), volumetric MRI, diffusion tensor imaging (DTI) and functional MRI (fMRI)
(Masters and Ances, 2014). Magnetic resonance spectroscopy of the brain, also known as 
proton magnetic spectroscopy, has demonstrated to show virus-induced neurological 
deterioration (Jarvik et al, 1993; McConnell et al, 1994). Regardless of the method used to 
evaluate the neurocognitive state, it is essential to perform longitudinal tests over time, or in 
the case of a cross sectional study, include appropriate matched controls. As pilot studies to 
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perturb latency and deplete persistent HIV infection move forward into the clinic, careful 
assessment of the CNS will be also important to insure that neurocognitive function is not 
impaired as an unwanted side effect of viral induction strategies, even as study patients 
maintain ART.
There are still many challenges to overcome in order to achieve an HIV cure. Therapies to 
target latent infection in resting CD4+ T cells are now undergoing extensive study, but at 
this early point in this endeavor, success is uncertain. Close behind this is the challenge of 
clearing infected cells, following their emergence from latency. The final frontier may be 
strategies to access privileged spaces such as the CNS. Initial efforts in this regard are likely 
to depend critically on animal model studies. Like therapy for childhood leukemia, success 
in eradication of established HIV infection may not come until we have developed specific 
therapies to reach the deepest hiding places in which the virus lurks.
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Proposed strategy to purge HIV cellular reservoirs, known as “shock and kill”. A first step 
consists in disrupting latency by agents such as vorinostat, which will cause HIV expression 
and new virions release. The presence of HAART will prevent new rounds of infection, and 
the reactivated cells will be cleared in a second step where immune clearance will be 
promoted through the activation of effector cells or the administration of targeted molecules.
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Table 1
Summary of models to study HIV latency.
Models to study HIV latency
Cellular models Animal models







  • Jurkat cells - Greene [4] - HuBLT [11]
    (J89, 2D10, - Lewin [5] - Macaque:
    J-Lat, JΔT) [1] - Spina [6] - Isolated from - T-cell Only
  • ACH-2 [2] - Karn [7] HIV+ individuals   Mouse(TOM)[12]   • SIV [14]
- Planelles [8] [10]
- Promonocytic - Siliciano [9] - HuSCID [13]   • RT-SHIV [15]
  • U1 [3]
[1]
(Jordan et al, 2003)
[2]
(Clouse et al, 1989)
[3]
(Folks et al, 1987)
[4]
(Lassen et al, 2012),
[5]
(Saleh et al, 2007),
[6]
(Spina et al, 2013) ,
[7]
(Tyagi et al, 2010)
[8]
(Bosque and Planelles, 2011)
[9]
(Yang et al, 2009)
[10]
(Siliciano and Siliciano, 2005)
[11]
(Denton et al, 2012)
[12]
(Honeycutt et al, 2013)
[13]
(Namikawa et al, 1988)
[14]
(Dinoso et al, 2009)
[15]
(Jiang et al, 2009)
J Neurovirol. Author manuscript; available in PMC 2016 June 01.
